New Data Demonstrate the Benefits of Early Use of UPTRAVI® (selexipag) in Delaying Disease Progression in a Broad Population of Patients with Pulmonary Arterial Hypertension (PAH) | Johnson & Johnson

New Data Demonstrate the Benefits of Early Use of UPTRAVI® (selexipag) in Delaying Disease Progression in a Broad Population of Patients with Pulmonary Arterial Hypertension (PAH)

08/30/2021

DownloadPDF 588 KB

Multimedia Files:

Questions? Please contact us:

investor-relations@its.jnj.com